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Inherited thrombocytopenia: novel Insights into megakaryocyte
maturation, proplatelet formation and platelet lifespan
Ben Johnson, Sarah J. Fletcher, & Neil V. Morgan
Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, UK
Abstract
The study of patients with inherited bleeding problems is a powerful approach in determining
the function and regulation of important proteins in human platelets and their precursor, the
megakaryocyte. The normal range of platelet counts in the bloodstream ranges from 150 000
to 400 000 platelets per microliter and is normally maintained within a narrow range for each
individual. This requires a constant balance between thrombopoiesis, which is primarily con-
trolled by the cytokine thrombopoietin (TPO), and platelet senescence and consumption.
Thrombocytopenia can be defined as a platelet count of less than 150 000 per microliter
and can be acquired or inherited. Heritable forms of thrombocytopenia are caused by muta-
tions in genes involved in megakaryocyte differentiation, platelet production and platelet
removal. In this review, we will discuss the main causative genes known for inherited throm-
bocytopenia and highlight their diverse functions and whether these give clues on the
processes of platelet production, platelet function and platelet lifespan. Additionally, we will
highlight the recent advances in novel genes identified for inherited thrombocytopenia and
their suggested function.
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Introduction
Inherited thombocytopenias (ITs) are a heterogeneous group of
disorders characterized by a sustained reduction in platelet count
manifesting as a bleeding diathesis. Since the discovery of disease
inheritance patterns in disorders such as Bernard Soulier
Syndrome (BSS), genetic studies of thrombocytopenia have
been a vital tool in determining megakaryocyte and platelet phy-
siology [1]. As a result of parallel whole exome and whole
genome sequencing over the past 5–10 years, we are discovering
increasing numbers of novel genes with a critical role in platelet
physiology. However, are any of these genes giving us clues to
platelet lifespan? Is IT predominately caused by a defect in the
process of platelet production or is there more to the story than
we currently know?
To date, there are 31 genes suspected to cause 27 separate
forms of inherited thrombocytopenia (Table I). The majority of
patients with thrombocytopenia present secondary to syndromic
disorders usually affecting the immune system or in cases of
immune thrombocytopenic purpura (ITP). However, a number
of cases present as a bleeding diathesis as a result of a reduced
platelet count, sometimes alongside additional platelet dysfunc-
tion, indicating an effect solely on cells of the hematopoietic
lineage. As a consequence of the varied phenotypic display and
clinical presentation of inherited thrombocytopenias, there are
several ways in which they are characterized. One such way,
which has been favored following molecular characterization of
the effect of mutations, is to group genes based upon their effect
on megakaryocyte differentiation, platelet production and platelet
function. Therefore, to understand whether a link to platelet life-
span can be established it is best to first consider all genes
implicated in a reduced platelet count.
Genes that effect megakaryocyte differentiation and
maturation
Like all blood cells, megakaryocytes are derived from hemato-
poietic stem cells (HSCs) via progressively differentiated progeni-
tor cells [2]. This is a process that is underpinned by the synthesis
and synergistic effect of the cytokine thrombopoietin (TPO)
through its receptor c-Mpl [3]. However, the commitment to
differentiate and commit along the myelo-erythroid lineage is
also highly regulated by transcription factors. One such transcrip-
tion factor is GATA1, which is critically regulated transcription-
ally [4]. Additional transcription factors such as Runt-related
transcription factor 1, encoded by the gene RUNX1, ETV6 and
FLI-1 in tandem with the transcriptional repressor GFI1B, ensure
maturation of the megakaryocytes by binding critical promoter
regions in crucial megakaryocyte-expressed genes [5, 6]. With the
exception of Friend of Gata-1 (FOG1), the co-factor to GATA1,
variants in the aforementioned hematopoietic transcription factors
have previously been shown to cause inherited thrombocytopenia
[7–11]. In addition, variants have also been observed in the TPO
receptor gene MPL, as well as in its ligand, encoded by the gene
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THPO in one large Micronesian family with affected individuals
displaying idiopathic aplastic anemia and mild thrombocytopenia
[12, 13]. As the crucial role of TPO and transcription factors in
megakaryocyte production is widely known, it is unsurprising that
variants within these genes are commonly found within patients
with inherited thrombocytopenia. However, clinical presentation
does vary (most likely as a result of secondary effects of tran-
scription factors and chemokines), but, all mutations are consis-
tent in their ability to reduce proliferation of CD34+ cells by
altering transcription profiles of genes crucial in megakaryocyte
development [14].
In addition to the aforementioned genes involved specifically
in the commitment to the proliferation towards megakaryocytes, a
number of other genes have putative roles in differentiation and
maturation. These include HOXA11, RBM8A, ANKRD26 and
NBEAL2.
Similar to FLI-1, ETV6 and AML-1, HOXA11 is a DNA-
binding protein, which is expressed, like many other home-
odomain box proteins, in human cord blood and hematopoie-
tic precursor cells [15]. The specific molecular mechanism
behind how variants in HOXA11 cause amegakaryocytic
thrombocytopenia with radio-ulnar synostosis syndrome has
yet to be established. However, it has been suggested that a
point mutation in the third helix of the homeobox domain can
lead to a reduction in CD61 expression in staurosporine-
induced K562 cells [15].
RBM8A, the gene encoding the exon junction splicing complex
component Y14, is interesting both in the genetic complexity of
the disease and in its proposed molecular mechanism.
Thrombocytopenia with absent radii (TAR) syndrome is known
currently as a result of the co-inheritance of a variably sized
deletion of the region surrounding 1q21.1, including RBM8A,
alongside one of two relatively high-frequency SNPs within the
regulatory region of RBM8A [16]. The clinical outcome is severe
but heterogeneous and seems to be determined by a number of
factors, including variable gene expression and possible epige-
netic modifiers. Little is known on the specific cellular effect of
the compound hypomorphic effect of mutations within RBM8A,
but a reduction in megakaryocyte progenitors is observed and is
thought to arise as a result of aberrant JAK2 signaling down-
stream of TPO [17, 18].
The production of intracellular granules, during megakaryo-
cyte maturation, from the budding of small vesicles containing
cargo from trans-Golgi network is crucial for the further differ-
entiation of platelets [19]. Platelet α-granules play a crucial role
in platelet function and amplification of activation during hemos-
tasis. A number of ITs, including GATA1-related
thrombocytopenia (RT) and GFI1B-RT, show reduced numbers of
Table I. Genetic causes of inherited thrombocytopenia, the encoded protein and their associated diseases. Grouped into their suggested role within
megakaryopoiesis, platelet production or clearance/other.
Area of mutational
effect Gene Protein Associated disease References
Megakaryopoiesis ANKRD26 Ankyrin repeat domain 26 ANKRD26-related thrombocytopenia [25]
ETV6 Transcription factor ETV6 THC5 [7]
FLI1 Friend leukaemia integration 1 transcription
factor
Paris Trousseau type thrombocytopenia/Jacobsen
(11q23 del)
[8]
FYB FYN-binding protein Novel thrombocytopenia [26]
GATA1 Erythroid transcription factor GATA1 related disease (XLT and XLTT) [9]
GFI1B Zinc finger protein Gfi-1b Grey Platelet Syndrome + novel
thrombocytopenia
[10]
HOXA11 Homeobox protein Hox-A11 Amegakaryocytic thrombocytopenia with radio-
ulnar synostosis
[74]
MPL Thrombopoietin receptor Congentical amegakaryocytic thrombocytopenia [12]
NBEAL2 Neurobeachin-like protein 2 Grey Platelet Syndrome [20]
RBM8A RNA-binding protein 8A Thrombocytopenia with absent radii [16]
RUNX1 Runt-related transcription factor Familial platelet disorder and predisposition to
AML
[11]
THPO Thrombopoietin Mild novel thrombocytopenia (heterozygous) [13]
Platelet production ACTN1 Alpha-actinin-1 Bleeding disorder, platelet-type 15 [36]
CYCS Cytochrome C CYCS-related thrombocytopenia [45]
GP1BA Platelet glycoprotein 1b alpha chain Bernard–Soulier Syndrome + Platelet type von-
Willebrand disease
[75]
GP1BB Platelet glycoprotein 1b beta chain [76]
GP9 Platelet glycoprotein IX [77]
ITGA2B Integrin alpha-Iib ITGA2B/ITGB3-related thrombocytopenia [78]
ITGB3 Integrin beta-3 [79]
MKL1 MKL/myocardin-like protein 1 Thrombocytopenia with immunodeficiency [31]
MYH9 Myosin 9 MYH9 related disease [80]
PRKACG cAMP-dependant protein kinase catalytic subunit
gamma
Bleeding disorder, platelet-type 19 [39]
TUBB1 Tubulin beta-1 chain TUBB1-related macrothrombocytopenia [29]
WAS Wiskott–Aldrich syndrome protein Wiskott-Aldrich syndrome, X-linked
thrombocytopenia
[81]
Platelet clearance/
other
ABCG5 ABC transporter G family member 5 Thromobocytopenia associated with
sitosterolaemia
[57]
ABCG8 ABC transporter G family member 8 [57]
ADAMTS13
GNE
Disintegrin/metalloproteinase with
thrombospondin motifs 13
Glucosamine (UDP-N-Acetyl)-2-Epimerase
TTP, Upshaw–Schulman syndrome
GNE myopathy with congenital
thrombocytopenia
[51]
[65]
SLFN14 Schalfen family member 14 Novel thrombocytopenia [62]
STIM1
vWF
Stromal interaction molecule 1
Von Willebrand factor
Stormorken Syndrome
Von Willebrand disease type 2B
[82]
[83]
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platelet α-granules. However, a complete absence of platelet α-
granules is observed in patients with Grey Platelet Syndrome
(GPS), a condition caused by genetic variations within NBEAL2
[20]. NBEAL2 localizes to the endoplasmic reticulum in platelets,
where it is likely to function in membrane trafficking; however,
the role of NBEAL2 in GPS and the subsequent reduction in
platelet count is still largely unknown. Nbeal2−/- mice do recapi-
tulate the phenotype of GPS, including an absence of platelet α-
granules as well as delayed megakaryocyte maturation, decreased
survival and decreased ploidy in cultured megakaryocytes [21].
Interestingly, however, a lack of Nbeal2 in mice does not affect
initial α-granule formation, packaging or transport to the budding
platelets within megakaryocytes [22]. Both GPS mice and
patients do develop premature myelofibrosis within the bone
marrow, which may be as a result of spontaneous granule release
or “leaking” from the megakaryocytes [22–24].
Another gene where variants have been shown to cause a
defect in megakaryocyte maturation resulting in reduced platelet
α-granules is ANKRD26. Like RBM8A, variants affect gene
expression and occur in the 5’-UTR of the gene, specifically in
a short stretch of nucleotides from c.-134G to c.-113A [25]. In
affected individuals, megakaryocytes are small, with hypolobu-
lated nuclei as a result of dysmegakaryopoiesis.
One of the most recently discovered genes known to cause
inherited thrombocytopenia is FYB. Although the effect of the
mutation has yet to be determined, a role in megakaryopoiesis has
been suggested due to a reduced percentage of mature megakar-
yocytes in the bone marrow [26].
It seems then that the progression of HSCs through the mega-
karyocytic lineage to achieve mature megakaryocytes is a prime
pathway to be disrupted by genetic mutation. Indeed, most var-
iants not only involve altered expression or downstream signaling
of the chemokine TPO, but many also affect additional signaling
pathways, leading to a wide range of secondary abnormalities.
Genes that affect pro-platelet formation and release
Following megakaryopoiesis, the next phase in platelet produc-
tion is pro-platelet formation and release of platelets from pro-
platelet tips [27]. As the expression profile alters to accommodate
new functional processes of the megakaryocyte, so do the genes
in which mutations mediate thrombocytopenia.
As megakaryocytes reach their mature state, they undergo
fundamental changes to be able to release platelets into circula-
tion via bone marrow sinusoids. These changes are underpinned
by cytoskeletal rearrangements and subsequent cellular signaling.
Causative mutations of IT are actually most commonly found to
functionally disrupt these processes.
The fundamental action leading to the release of platelets is the
production of proplatelet extensions from a demarcated mem-
brane system. Once in the vascular niche, mature megakaryocytes
produce protrusions by microtubule sliding [28]. β1-Tubulin is the
main isoform within human megakaryocytes and mutations
within the gene encoding TUBB1 are known to cause an auto-
somal dominant form of inherited thrombocytopenia [29].
Like β1- tubulin, F-actin is present throughout proplatelets and
allows proplatelet branching. These actin polymerization pro-
cesses are promoted by nucleation factors such as WASp, encoded
by WAS, which is selectively expressed in hematopoietic cells
[30]. Mutations in WAS generally follow a genotype–phenotype
correlation, where variants which abolish WASp expression or
result in the expression of a truncated protein are associated with
Wiskott–Aldrich Syndrome (WAS). Those causing decreased
levels of WASp result in X-linked thrombocytopenia (XLT).
Missense variants are most common in XLT and those occurring
in the first three coding exons and the correlating EVH1/WH1
domain tend to cause the mild X-linked thrombocytopenia, which
is not associated with the immunodeficiency observed in WAS.
Actin polymerization and the production of F-actin has
recently been shown to be affected in a patient with a homozy-
gous nonsense mutation within the gene encoding megakaryo-
blastic leukemia 1; MKL1 [31]. In addition to severe
immunodeficiency, the patient suffers from mild-to-moderate
thrombocytopenia (platelet counts 50–150 × 109/l). The cause
of this is thought to be a loss of filamentous actin production
due to a reduction in globular actin (G-actin) coupled with a
reduction in megakaryocyte migration, which phenocopies mice
deficient for murine Mkl1 [32, 33].
Myosins, in particular, IIA and IIB, are also involved in
proplatelet formation by interacting with actin filaments generat-
ing contractile forces. One myosin, the heavy chain of nonmuscle
myosin IIA (NMMHC-IIA) encoded by the gene MYH9, is
thought to play a slightly different role as mutations actually
increase proplatelet formation [34]. Mutations causing MYH9-
related disease therefore cause thrombocytopenia through the
most proximal part of platelet formation, where a disruption in
the Rho-Rho kinase-myosin IIA pathway leads to a lack of reac-
tivation of NMMHC-IIA. This is a process that is required for the
budding of preplatelets and subsequent separation into platelets;
therefore, mutations in MYH9 cause a loss of induced fragmenta-
tion of preplatelets promoting the formation of a reduced number
of large platelets [35].
Cross linking of actin filaments is required for their bind-
ing to the actin cytoskeleton. This is mediated in structures
known as actin-binding domains (ABDs), which contain α-
actinin. One of the four isoforms, which is expressed in
megakaryocytes, is ACTN1. To date, 13 pathogenic missense
variants have been found within the encoding gene ACTN1;
all cause a mild dominantly inherited thrombocytopenia where
megakaryocyte tips are reduced in number, increased in size
and exogenous expression of the mutations inhibits actin fila-
ment assembly [36].
Filamins, via an N-terminal ABD, anchor the filaments to
the cell membrane. Variations in the most abundant filamin in
platelets, FLNA, are known to cause periventricular nodular
heteropia as well as an isolated thrombocytopenia [37]. Some
patient megakaryocytes from cultured peripheral CD34+
blood cells show frayed structures and signs of cytoplasmic
degradation favoring abnormal distribution into incorrectly
packaged platelet-like fragments. However, a population of
platelets negative for FLNA was observed, indicating it may
not be necessary in proplatelet formation, therefore, playing a
noncrucial role [37].
There may remain an important role for FLNA in platelet
biogenesis as its proteolysis is protected by phosphorylation at
S2152 by cAMP-dependent protein kinase A, which is similar to
the protection observed in GP1bβ [38]. The kinase consists of two
catalytic subunits, the y-isoform of which is encoded by
PRKACG. To date, only one variant has been found within
PRKACG, which results in rapid degradation of FLNA and a
reduction in the percentage of proplatelet-bearing megakaryo-
cytes [39].
Complementary to the physical formation of proplatelets is
the relay of extracellular signals to the cytoskeleton via mem-
brane-bound receptors. Two main receptors are affected by
mutations in inherited thrombocytopenia. The first is the
receptor for Von-Willebrand factor (VWF), GP1b-IX-V.
Consisting of four subunits, GP1bα, GP1bβ, GPIX and GPV,
activation of the receptor via interaction of VWF with GP1bα
relays signals to aid in proplatelet formation. Variants in the
encoding genes, GP1BA, GP1BB and GP9, are known to
cause both monoallelic and biallelic forms of BSS and lead
DOI: 10.3109/09537104.2016.1148806 Inherited thrombocytopenia 3
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to a reduction in proplatelet-forming megakaryocytes in cul-
ture [40, 41].
The second receptor known to be affected in the spectrum
of inherited thrombocytopenias is the integrin GPIIb-IIIa, the
receptor for fibrinogen. Encoded by the genes ITGA2B and
ITGB3, mutations are associated with Glanzmann throm-
basthenia (GT). GT often causes bleeding with no alteration
in platelet count; however, gain of function variants exists that
lead to a thrombocytopenia, suggesting a role for the interac-
tion of fibrinogen for platelet biogenesis [42]. Recently, it has
been suggested that cytoskeleton rearrangement can be
impaired, arresting actin turnover at the stage of polymeriza-
tion, by permanent triggering of the aIIbβ3-mediated outside-
in signaling [43]. Murine megakaryocytes transduced with an
ITGB3 variant (c.del647-683) generated proplatelets with a
reduced number of large tips and barbell-proplatelets, sug-
gesting impaired cytoskeletal remodeling as the cause of
thrombocytopenia in patients with GT.
One gene whose involvement in platelet production cur-
rently, through the intrinsic apoptosis pathway, is controver-
sial is Cytochrome C (CYCS). CYCS initiates apoptosis
through the activation of caspase 9 and subsequently caspase
3, a dysregulation of which was originally suggested as a
feature of platelet production [44, 45]. To date, two variants
(Y49H [p.48 in original publication] and G42S [p.41 in ori-
ginal publication]) have been observed in the apoptosis-linked
gene CYCS [45, 46]. Indeed, electron microscopy of patient
bone marrow shows intramedullary naked megakaryocyte
nuclei, indicative of dysregulated megakaryopoiesis and pre-
mature platelet release. Furthermore, mouse lung fibroblasts
transduced with CycsY48H and CycsG41S show increased apop-
totic activity in response to staurosporine. It was therefore
first believed that apoptosis had a fundamental role in the
timing of pro-platelet release, hypothesizing that inhibition of
actin polymerization, a process required for the formation of
proplatelets, activates the apoptotic pathway [47]. However,
platelet production can proceed regardless of both the intrin-
sic and extrinsic apoptotic pathways, suggesting there is more
to the role of apoptosis in megakaryopoiesis than currently
meets the eye [48].
Genes with a molecular function outside of platelet
production
It is clear and obvious that the fundamental processes governing the
production of platelets are easily affected by deleterious mutations
leading to thrombocytopenia. This is summarized in Figure 1.
However, disease affecting megakaryocytes and the formation of
platelets do not cover all of the genes currently known to cause
thrombocytopenia. These alternative genes do not play role in mega-
karyopoiesis/thrombopoiesis. Their molecular causes of disease are
unique or not currently known and it is best to consider them indivi-
dually and separate from the aforementioned genes.
VWF is particularly well known due to its importance in hemos-
tasis, illustrated with the functional deficiency of vWF known as von
Willebrand disease (VWD), awell-characterized and common collec-
tion of bleeding disorders. One particular type of VWD is known as
type 2B, which refers to gain-of-function mutations that increase the
affinity of vWF for GP1b on the platelet surface. The net effect of this
is the presence of giant platelets due to continuous interactions
between vWF and GP1bα disrupting megakaryopoiesis [49]. More
interestingly, though, large multimers of vWF associated with plate-
lets are also observed in VWD type 2B patients [50]. In vWF knock-in
mice, these specific complexes are taken up efficiently by macro-
phages in the liver and spleen, indicating an increased clearance of
platelets from the circulation.
One interesting gene with a mechanism of pathogenesis for throm-
bocytopenia is ADAMTS13. Variants in the metalloproteinase
ADAMTS13 are the genetic cause of Upshaw–Schulman syndrome,
alternatively known as congenital thrombotic thrombocytopenic pur-
pura (TTP) [51]. TTP is a life-threatening systemic illness character-
ized by hemolytic anemia, neurological symptoms, renal dysfunction
as well as thrombocytopenia. Normally in-circulation ADAMTS13 is
the von Willebrand factor-cleaving protease. However, loss-of-func-
tion mutations within ADAMTS13 and subsequent TTP result in vWF
not being cleaved at the Tyr 842-Met 843 peptide bond resulting in the
accumulation of large vWF multimers similar to a gain-of-function
mutations in vWF[52]. Unlike VWD type 2B, the reduction in platelet
count observed in TTPmay be due to platelet aggregation under sheer
stress because of an inability to cleave vWF [53]. This has the
propensity to explain vWF–platelet aggregation in the arterioles and
capillaries, a phenotype characteristic of TTP.
Defective megakaryocyte 
differentiation/maturation
ANKRD26
ETV6
FLI1
FYB
GATA1
GFI1B
HOXA11
MPL
NBEAL2
RBM8A
RUNX1
THPO
Defective proplatelet 
formation/release
ACTN1
CYCS
FLNA
GP1BA/GP1BB/GP9
ITGA2B/ITGB3
MKL1
MYH9
PRKACG
TUBB1
WAS
proliferation
HSC
HSCHSCHSC
CMP
MEP
Progenitors 
Cytoplasmic 
maturation Proplatelet 
formation 
Platelet 
production 
PreplateletsImmature 
Megakaryocytes 
Megakaryocytes 
Senescence/consumption/
death/other 
Other
ABCG5/8
ADAMTS13
GNE
SLFN14
STIM1
VWF
Figure 1. Megakaryopoiesis, platelet production
and other causes of IT. Differentiation from
HSCs to platelets proceeds by a number of
intermediate cell types, which leads to the for-
mation of megakaryocytes which fragment via
proplatelet formation to produce mature plate-
lets. This process is driven by a number of genes
encoded a number of transcription factors and
proteins. Defects in these genes have been
shown to give rise to thrombocytopenia by
mostly affecting the relevant stage of platelet
production they are labeled under. Variants that
do not play a role in platelet production by
megakaryopoiesis are included in the third sub-
group entitled platelet removal, death and other.
HSC: Hematopoietic stem cell, CMP: Common
myeloid progenitor, MEP: Megakaryocyte-ery-
throid progenitor.
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An increased clearance of platelets is also present in patients
with activating mutations of STIM1 within Stormorken syndrome
and more recently York syndrome [54, 55]. Platelets in these
patients are circulating in a preactivated state due to a constitu-
tively active store operated Ca(2+) release-activated Ca(2+)
(CRAC) channel and increase in Ca2+ entry. The net effect of
which causes a reduction in the number of circulating platelets,
but not due to an early ageing of platelets but an increased
clearance of pre-activated platelets within the spleen, which is
recapitulated in Stim1Sax/+ mice [56].
One interesting case of thrombocytopenia is as a secondary
symptom with Sitosterolemia. Sitosterolemia is a rare, autosomal
recessive disease caused by mutations in two adjacent ATP-bind-
ing cassette transport genes; ABCG5 and ABCG8 [57].
Hematological abnormalities, including thrombocytopenia, are a
symptom of this complex disorder which results in decreased
excretion and therefore accumulation of dietary sterols. ABCG5
and ABCG8, which normally act as a heterodimeric efflux pump,
are not present on blood cells or platelets. The effects of muta-
tions are therefore considered to be because of the relative toxicity
they possess in high levels to cellular membranes [58, 59].
Interestingly, in ABCG5/ABCG8 knock-out mice, which are fed
on high-plant-sterol diet, platelets are noted to be hyper-activata-
ble and show impaired function [60].
One of the most recently discovered genes known to cause
inherited thrombocytopenia is SLFN14. SLFN14 has recently
been identified as an endoribonuclease, functioning to destroy
mRNA, which cannot be correctly translated, and causes degra-
dation of ribosomal subunits [61]. Three consecutive heterozy-
gous missense mutations were identified in three unrelated
families predicted to encode substitutions K218E, K219N and
V220D [62]. Alongside the reduced number of platelets, they
also show platelet dysfunction and an increased immature platelet
fraction, a noninvasive measure indicative of increased platelet
clearance. However, the exact mechanism through which muta-
tions in SLFN14 mediate thrombocytopenia and aberrant platelet
function is unknown.
There is similar lack of knowledge for the molecular effect of
one of the most recently reported causative genes of IT, GNE,
Mutations within the gene encoding Glucosamine (UDP-N-
Acetyl)-2-Epimerase/N-Acetylmannosamine kinase (GNE) are
most noted as the molecular cause of Sialuria (OMIM#269921)
and Hereditary Inclusion Body Myopathy (HIBM;
OMIM#600737) [63, 64]. Recently, however, two related indivi-
duals presented with GNE myopathy associated with congenital
thrombocytopenia [65]. Both patients suffered from a severe
reduction in platelet count; however, the hematological effect of
mutations within GNE has yet to be suggested.
Clearly, it is not solely platelet production that is affected
by deleterious mutation. Lifespan can be inadvertently altered
by pre-activation, the production of aggregated multimers and
by toxicity. However, with platelet lifespan so intrinsically
controlled by levels of pro-apoptotic proteins versus pro-sur-
vival proteins, why is it that no variants have thus far been
discovered in this specific pathway? For us to understand this
further, we need to consider how platelet lifespan is con-
trolled and how it could theoretically be disturbed.
In platelets, it was long suggested that the Bcl-2 family of pro-
survival proteins was required to suppress the pro-apoptotic sig-
nals of BAK and BAX [66]. It was Mason et al. who first
established the link of degradation of Bcl-XL (encoded in humans
by BCL2L1) to platelet death [67]. This subsequent loss of the
restrained pro-apoptotic signal was therefore suggested as a mole-
cular clock for platelet lifespan, an idea which was pioneered by
the group of B. Kile. [67]. Megakaryocyte-specific deletion of
Bcl-xL in mice does indeed profoundly reduce the platelet count to
2% of that observed in wild-type mice [68]. Additionally, platelet
survival is markedly increased in Bak and Bax knock out and
megakaryocyte-specific depleted mice [68].
So in a process so highly controlled by expression and protein
levels, why are there not any variants in Bcl-xL or Bak/Bax that
are known to cause thrombocytopenia?
There are two possible explanations. One is that loss-of-function
variants in BCL2L1 are lethal. While Bcl-XL is involved in prevent-
ing mature megakaryocytes from apoptosis it is not essential alone
for their growth and development, whereas presence of either Bcl-
XL or Mcl-1, another member of the pro survival Bcl-2 family, is
required for organism viability [69]. However, Bcl-XL’s functions
are not limited solely to platelet lifespan and it follows a wide
expression pattern both in adult and in embryonic tissue [70, 71].
Interestingly, Jak2, which is thought to positively regulate Bcl-XL
expression in megakaryoblastic cells, is associated with decreased
survival when selectively deleted in mouse hematopoietic cells [69,
72]. Therefore, at this moment in time, it is difficult to rule out the
possibility that an organism-specific effect may be occurring within
humans where genetic variations in BCL2L1 are simply not viable.
The other point to consider is the possibility that we haven’t
determined a molecular cause of disease within BCL2L1 or any
other genes involved in platelet lifespan simply due to their rarity.
The most recent large-scale targeted genomics study into inherited
thrombocytopenia revealed that only 50% of patients have a defined
genetic etiology of disease [73]. With the progression of next-genera-
tion sequencing and the introduction of large-throughput whole
exome and whole genome sequencing, new variants are being dis-
covered in these previously undiagnosed patients [7, 62]. Inherited
thrombocytopenias though, as a spectrum of disorders, are still fun-
damentally underdiagnosed. Yet, as our knowledge increases, we
learn more about the effect of deleterious variants gaining insights
into new mechanisms within platelet production, function and
lifespan.
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